



## CARBON REDUCTION PLAN

**Supplier Name:** Provepharm UK Ltd

**Publication date :** 23<sup>rd</sup> March 2026

### Commitment to achieving Net Zero

Provepharm UK Ltd is committed to achieving a Net Zero emissions by 2050.

### Baseline Emissions Footprint

Provepharm UK Ltd, created in 2023, is a subsidiary of Provepharm Life Solutions based in 22, rue Marc Donadille — 13013 Marseille — France.

In line with its environmental strategy, Provepharm Life Solutions actively works to decarbonize its operations, both at its site and across its entire value chain. In 2021, the company carried out its first greenhouse gas (GHG) emissions assessment using the ACT methodology developed by ADEME<sup>1</sup> and the Carbon Disclosure Project<sup>2</sup> (CDP), and began identifying potential reduction measures.

Provepharm Life Solutions has undergone significant organisational change since the 2021 assessment was completed. This coupled with the evolution of carbon assessment methodologies and available sectoral data in the pharmaceutical industry led the group to conduct a new, comprehensive evaluation of all Scope 1, 2, and 3 emissions in 2024. This assessment was carried out by a specialized consultancy in accordance with the GHG Protocol corporate standard, ensuring transparent and robust results for all national and international stakeholders.

As advised in the previous Carbon Reduction Plan, the year 2024 is considered the baseline year for Provepharm UK Ltd's decarbonization roadmap. Provepharm UK

---

<sup>1</sup> <https://www.ademe.fr>

<sup>2</sup> [www.cdp.net/en](http://www.cdp.net/en)

#### PROVEPHARM UK Ltd.

Business Address  
First Floor  
Building 2  
Croxley Green Business Park  
Watford  
WD18 8YA  
+44 333 042 8123

Registered Address  
Wilberforce House  
Station Road  
London  
NW4 4QE  
Company Registration Number 14628786



Ltd supports and adopts the Carbon Reduction Plan of the parent company, using this updated baseline to define annual reduction targets.

[Baseline year : 2024](#)

| Baseline year emissions 2024 |                    |
|------------------------------|--------------------|
| Emissions                    | tCO <sub>2</sub> e |
| Scope 1                      | 139                |
| Scope 2                      | 70                 |
| Scope 3                      | 69 339             |
| <b>TOTAL EMISSIONS</b>       | <b>69 548</b>      |

### Emissions reduction targets

In order to continue our progress to achieving Net Zero, Provepharm Life Solutions has adopted the following carbon reduction targets based on the Science Based Targets methodology (SBTi):

- Annual reduction of 7 % of emissions from 2024 to 2033 across Scope 1, 2, and 3.
- These targets will be regularly reviewed and updated to align with the forthcoming 2025–2050 Carbon Reduction Plan.

We project that carbon emissions will decrease over the next five years to 41 848 tCO<sub>2</sub>e by 2031. This is a reduction of 40 %.

### Carbon reduction projects

Provepharm has identified and initiated a range of environmental management measures to reduce its carbon emissions across Scope 1, 2, and 3. These include:

- Transitioning the Marseille site to low-carbon electricity sources (e.g., wind energy).



- Gradually shifting selected supply chain and freight operations from air to sea transport.
- Improving site waste management to enable energy recovery and associated emissions reduction.

These initiatives are at various stages of implementation and will contribute to the ongoing reduction of carbon emissions. Their effectiveness will be monitored as part of Provepharm's annual carbon reporting, ensuring progress is tracked transparently and that actions are adjusted as needed to meet reduction targets.

In the future we hope to implement further measures such as

- Encouraging the use of remote meetings and limiting non-essential business travel;
- Promoting lower-carbon transport options, such as rail travel over air travel where feasible;
- Optimising working practices through flexible working arrangements to reduce commuting-related emissions;
- Reducing paper use and supporting the digitalisation of business activities
- Raising employee awareness of environmental best practices in day-to-day operations.

## **Declaration and Sign Off**

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard 3 and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

---



This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

*Signed on behalf of the Supplier:*

Signé par :

*Hélène Thomas*

62B1CC32E5C94D2...

Date 22-mars-2026 | 08:30 CET

Hélène Thomas  
Director – Provepharm UK Ltd